96 related articles for article (PubMed ID: 12401904)
21. Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months.
Huang O; Chen C; Wu J; Chen S; Chen X; Liu G; Hu Z; Lu J; Wu J; Shao Z; Shen Z; Shen K
BMC Cancer; 2009 Oct; 9():375. PubMed ID: 19845944
[TBL] [Abstract][Full Text] [Related]
22. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of neoadjuvant docetaxel/ vinorelbine followed by surgery and adjuvant doxorubicin/cyclophosphamide in women with stage II/III breast cancer.
Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
Clin Breast Cancer; 2006 Feb; 6(6):511-7. PubMed ID: 16595034
[TBL] [Abstract][Full Text] [Related]
24. Epirubicin/vinorelbine as first line therapy in metastatic breast cancer.
Baldini E; Tibaldi C; Chiavacci F; Di Lieto M; Fioretto L; Giallom-bardo A; Taviani R; Ghezzi P; Bolognini A; Conte P
Breast Cancer Res Treat; 1998 May; 49(2):129-34. PubMed ID: 9696395
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of epirubicin, vinorelbine and cisplatin in advanced breast cancer.
Garrone O; Principe E; Occelli M; Mercuri M; Numico G; Granetto C; Di Costanzo G; Rattazzi PD; Merlano M
Anticancer Drugs; 2004 Jan; 15(1):23-7. PubMed ID: 15090739
[TBL] [Abstract][Full Text] [Related]
26. A Cisplatin and vinorelbine (NP) regimen as a postoperative adjuvant chemotherapy for completely resected breast cancers in China: final results of a phase II clinical trial.
Gao LL; Huang XE; Zhang Q; Tang JH
Asian Pac J Cancer Prev; 2011; 12(1):77-80. PubMed ID: 21517235
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors of survival in pathologic incomplete response patients with locally advanced breast cancer after neoadjuvant chemotherapy.
Huang O; Jiang M; Chen XS; Wu JY; Chen WG; Li YF; Shen KW
Cell Biochem Biophys; 2015 Mar; 71(2):1181-90. PubMed ID: 25427887
[TBL] [Abstract][Full Text] [Related]
28. A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer.
Esteban E; de Sande G; Puertas J; Fra J; Palacio I; Vieitez JM; Fernández JL; Muñiz I; Modollel A; Carrasco J; Sala M; Lacave AJ
Breast Cancer Res Treat; 2000 Jul; 62(2):127-33. PubMed ID: 11016750
[TBL] [Abstract][Full Text] [Related]
29. Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer.
Espinosa E; Morales S; Borrega P; Casas A; Madroñal C; Machengs I; Illarramendi JA; Lizón J; Moreno JA; Belón J; Janáriz J; de la Puente M; Checa T; Mel JR; González Barón M
Cancer Chemother Pharmacol; 2004 Dec; 54(6):546-52. PubMed ID: 15316749
[TBL] [Abstract][Full Text] [Related]
30. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
[TBL] [Abstract][Full Text] [Related]
31. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL
J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557
[TBL] [Abstract][Full Text] [Related]
32. A Phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma.
Morrell LE; Lee YJ; Hurley J; Arias M; Mies C; Richman SP; Fernandez H; Donofrio KA; Raub WA; Cassileth PA
Cancer; 1998 Feb; 82(3):503-11. PubMed ID: 9452268
[TBL] [Abstract][Full Text] [Related]
33. A clinical phase II study of a non-anthracycline sequential combination of cisplatin-vinorelbine followed by docetaxel as first-line treatment in metastatic breast cancer.
Shamseddine AI; Otrock ZK; Khalifeh MJ; Yassine HR; Charafeddine M; Abdel-Khalek Z; Chehal A; Bitar N; Jalloul R; Dheiny M; Dandashi A; Wehbeh M; El-Saghir NS
Oncology; 2006; 70(5):330-8. PubMed ID: 17164589
[TBL] [Abstract][Full Text] [Related]
34. Alternating intravenous and oral vinorelbine plus epirubicin with pegfilgrastim as neoadjuvant treatment of locally advanced breast cancer.
Livi L; Paiar F; Santini R; De Luca Cardillo C; Galardi A; Di Cosmo D; Borghesi S; Agresti B; Nosi F; Gavilli S; Biti GP
Anticancer Drugs; 2006 Oct; 17(9):1081-5. PubMed ID: 17001182
[TBL] [Abstract][Full Text] [Related]
35. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
36. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).
Ejlertsen B; Mouridsen HT; Langkjer ST; Andersen J; Sjöström J; Kjaer M;
J Clin Oncol; 2004 Jun; 22(12):2313-20. PubMed ID: 15197192
[TBL] [Abstract][Full Text] [Related]
37. Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer.
Fountzilas G; Papadimitriou C; Aravantinos G; Nicolaides C; Stathopoulos G; Bafaloukos D; Kalofonos H; Ekonomopoulos T; Skarlos D; Pavlidis N; Dimopoulos AM
Oncology; 2001; 60(3):214-20. PubMed ID: 11340372
[TBL] [Abstract][Full Text] [Related]
38. First-line chemotherapy with fluorouracil-epirubicin-navelbine (FEN) combination in advanced breast cancer.
Ardavanis A; Tryfonopoulos D; Orphanos G; Ioannidis G; Karamouzis M; Rigatos G
Anticancer Res; 2005; 25(6C):4493-8. PubMed ID: 16334132
[TBL] [Abstract][Full Text] [Related]
39. 5-year results of cisplatin-epirubicin-vinorelbine (PEV) combination as primary chemotherapy in T2-3, N0-2 breast cancer patients: a multicentre phase II study.
Barni S; Visini M; Piazza E; Ionta MT; Ardizzoia A; Arnoldi E; Fava S; Pinotti G; Torretta F; Corradini G; Villa S; Nosenzo AM; Massidda B; Cazzaniga ME
Anticancer Res; 2007; 27(4C):3019-24. PubMed ID: 17695490
[TBL] [Abstract][Full Text] [Related]
40. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.
De Maio E; Pacilio C; Gravina A; Morabito A; Di Rella F; Labonia V; Landi G; Nuzzo F; Rossi E; Silvestro P; Botti G; Di Bonito M; Curcio MP; Formichelli F; La Vecchia F; Staiano M; Maurea N; D'Aiuto G; D'Aiuto M; Thomas R; Signoriello G; Perrone F; de Matteis A
BMC Cancer; 2007 Mar; 7():50. PubMed ID: 17374151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
